Sol-Gel net loss narrows to $3.7 million on lower R&D spending
Sol-Gel Technologies (NASDAQ:SLGL) reported a narrowed net loss for the first quarter of 2026, driven by a sharp reduction in research and development expenses as the clinical-stage biotechnology firm solidified its financing footprint.
The dermatology company posted a net loss of $3.7 million, or $1.31 per share, for the three months ended March 31.
This compares to a net loss of $8.8 million recorded during the same period last year.
The narrower deficit was primarily achieved through disciplined internal cost management, as research and development expenses fell to $2.8 million from $8.8 million in the prior year's first quarter.
Top-line revenue for the period dipped to $0.1 million, down from $1 million in the first quarter of 2025, a shift reflecting the typical lumpy timing of licensing milestones and product supply revenues for clinical-stage firms.
Despite the lower revenue footprint, Sol-Gel substantially fortified its balance sheet during the period, successfully closing an oversubscribed underwritten public offering that raised $33.1 million from specialized healthcare investors.
The fresh financing allowed Sol-Gel to conclude the quarter with $52.8 million in cash, deposits, and marketable securities.
Management projects that this expanded liquidity pool is sufficient to fully fund the company's core operations and clinical pipeline into the first quarter of 2028.
The capital reserve will primarily support the ongoing development of its lead drug candidate, SGT-610 (patidegib gel), which is currently undergoing Phase 3 clinical testing for the prevention of basal cell carcinomas in patients with Gorlin syndrome.
Sol-Gel remains on track to report critical top-line data from this pivotal registration trial in the fourth quarter of 2026.
The operational roadmap was further reinforced by recent regulatory and commercial developments.
The company received a Notice of Allowance from the U.S. Patent and Trademark Office for a vital method-of-use patent covering SGT-610, securing intellectual property protection for the asset until 2044.
On the commercial front, Sol-Gel expanded its global footprint by signing an exclusive licensing agreement with Sun Pharmaceutical Industries to market its approved acne cream, TWYNEO, in India, while continuing parallel discussions to broaden its global distribution partnerships.